Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-003 in healthy volunteers
NCT06604949Phase 1Active, not recruiting
- Sponsor
- LongBio Pharma
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic spontaneous urticaria (CSU) comparing LP-003 with Placebo (2 arms). Primary endpoint: Adverse Events at 12 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
LP-003
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06604949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06604949.